ACMT Position Statement: Caring for Patients with Opioid Use Disorder during Coronavirus Disease Pandemic

Centers for Disease Control and Prevention. Healthcare facilties: Managing operations during the COVID-19 pandemic.https://www.cdc.gov/coronavirus/2019-ncov/hcp/guidance-hcf.html#KeyConsiderations. Accessed 7 July 2020. Medicare telemedicine health care provider fact sheet. Centers for Medicare and Medicaid services https://www.cms.gov/newsroom/fact-sheets/medicare-telemedicine-health-care-provider-fact-sheet. Accessed 7 July 2020. Substance Abuse and Mental Health Services Administration. FAQs: Provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency. https://www.samhsa.gov/sites/default/files/faqs-for-oud-prescribing-and-dispensing.pdf. Accessed 7 July 2020. Marino R, Perrone J, Nelson LS, Weigand TJ, Schwarz ES, Wax PM, et al. ACMT position statement: removing the waiver requirement for prescribing buprenorphine for opioid use disorder. J Med Toxicol. 2019;15:307–9.